BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. World J Gastroenterol 2018; 24(2): 161-169 [PMID: 29375202 DOI: 10.3748/wjg.v24.i2.161] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 60] [Article Influence: 16.8] [Reference Citation Analysis]
Number Citing Articles
1 Liu YS, Chang PY, Liang PC, Ou MC, Hwang JI, Chen CH. Safety and Efficacy of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T). J Hepatocell Carcinoma 2022;9:811-21. [PMID: 35996398 DOI: 10.2147/JHC.S374555] [Reference Citation Analysis]
2 Ghosh A, Gupta V, Al Khalifah A, Akhter NM. Transradial versus transfemoral arterial access in DEB-TACE for hepatocellular carcinoma. JCIS 2022;12:38. [DOI: 10.25259/jcis_47_2022] [Reference Citation Analysis]
3 Shang C, Ke M, Liu L, Wang C, Liu Y, Zheng X. Exosomes From Cancer-Associated Mesenchymal Stem Cells Transmit TMBIM6 to Promote the Malignant Behavior of Hepatocellular Carcinoma via Activating PI3K/AKT Pathway. Front Oncol 2022;12:868726. [PMID: 35720012 DOI: 10.3389/fonc.2022.868726] [Reference Citation Analysis]
4 Silk T, Silk M, Wu J. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World J Gastroenterol 2022; 28(23): 2561-2568 [DOI: 10.3748/wjg.v28.i23.2561] [Reference Citation Analysis]
5 Deng J, Wen F. Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do? Front Oncol 2022;12:824799. [PMID: 35425716 DOI: 10.3389/fonc.2022.824799] [Reference Citation Analysis]
6 Mohr I, Vogeler M, Pfeiffenberger J, Sprengel SD, Klauss M, Radeleff B, Teufel A, Chang D, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-021-03900-3] [Reference Citation Analysis]
7 Ren Y, Guo Y, Chen L, Sun T, Zhang W, Sun B, Zhu L, Xiong F, Zheng C. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma. Cancer Control 2022;29:10732748221076806. [PMID: 35343254 DOI: 10.1177/10732748221076806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mostafa N, Salem A, Mansour SZ, El-Sonbaty SM, Moawed FSM, Kandil EI. Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges. Technol Cancer Res Treat 2022;21:15330338221085376. [PMID: 35382635 DOI: 10.1177/15330338221085376] [Reference Citation Analysis]
9 Razi M, Jianping G, Xu H, Ahmed MJ. Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma. J Interv Med 2021;4:11-4. [PMID: 34805941 DOI: 10.1016/j.jimed.2020.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Isaac A, Mohamed SM, Ahmed OA, Hassan AGM, Rasmy HS. Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment. Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00078-5] [Reference Citation Analysis]
11 Gao X, Chen Z, Chen Z, Liu X, Luo Y, Xiao J, Gao Y, Ma Y, Liu C, Leo HL, Yu H, Guo Q. Visualization and Evaluation of Chemoembolization on a 3D Decellularized Organ Scaffold. ACS Biomater Sci Eng 2021. [PMID: 34735119 DOI: 10.1021/acsbiomaterials.1c01005] [Reference Citation Analysis]
12 Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer 2021;10:451-60. [PMID: 34721507 DOI: 10.1159/000516605] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Muhammad H, Tehreem A, Ting PS, Gurakar M, Li SY, Simsek C, Alqahtani SA, Kim AK, Kohli R, Gurakar A. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. J Clin Transl Hepatol 2021;9:738-48. [PMID: 34722189 DOI: 10.14218/JCTH.2021.00125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
14 Liu KC, Lv WF, Lu D, Hou CL, Xie J, Lu YH, Cao QS, Tan YL, Zhang YZ, Liu J. Initial Experience of Drug-Eluting Bead-Transcatheter Arterial Chemoembolization After Lipiodol-Based Transcatheter Arterial Chemoembolization Failure for Patients with Advanced Hepatocellular Carcinoma. Cancer Manag Res 2021;13:7973-80. [PMID: 34703317 DOI: 10.2147/CMAR.S332571] [Reference Citation Analysis]
15 Zhang J, Feng GA, Li Y, Wang W. Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer. Asia Pac J Clin Oncol 2021. [PMID: 34708554 DOI: 10.1111/ajco.13660] [Reference Citation Analysis]
16 Cao L, Zhu YQ, Wu ZX, Wang GX, Cheng HW. Engineering nanotheranostic strategies for liver cancer. World J Gastrointest Oncol 2021; 13(10): 1213-1228 [PMID: 34721763 DOI: 10.4251/wjgo.v13.i10.1213] [Reference Citation Analysis]
17 Lyu T, Yao H, Wang J, Song L, Tong X, Zou Y. Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus. Clin Res Hepatol Gastroenterol 2021;:101819. [PMID: 34619365 DOI: 10.1016/j.clinre.2021.101819] [Reference Citation Analysis]
18 Kong D, Jiang T, Liu J, Jiang X, Liu B, Lou C, Zhao B, Carroll SL, Feng G. Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal. Drug Deliv 2020;27:1729-40. [PMID: 33307843 DOI: 10.1080/10717544.2020.1856219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wessner CE, Shaw CM, Stanczak M, Forsberg F, Lyshchik A, Tan A, Eisenbrey JR. Contrast-enhanced Ultrasound Identifies Patent Feeding Vessels in Transarterial Chemoembolization Patients With Residual Tumor Vascularity. Ultrasound Q 2020;36:218-23. [PMID: 32890324 DOI: 10.1097/RUQ.0000000000000513] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Facciorusso A, Paolillo R, Tartaglia N, Ramai D, Mohan BP, Cotsoglou C, Chandan S, Ambrosi A, Bargellini I, Renzulli M, Sacco R. Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00318-2. [PMID: 34193367 DOI: 10.1016/j.dld.2021.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Lin CY, Liu YS, Pan KT, Chen CB, Hung CF, Chou CT. The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment. Sci Rep 2021;11:12277. [PMID: 34112836 DOI: 10.1038/s41598-021-91021-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Fukushima T, Morimoto M, Kobayashi S, Ueno M, Sano Y, Kawano K, Asama H, Nagashima S, Maeda S. Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma. Mol Clin Oncol 2021;14:119. [PMID: 33903825 DOI: 10.3892/mco.2021.2281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Yağcı-Küpeli B, Ballı T. Hepatoblastoma treated successfully with drug-eluting bead transarterial chemoembolization: Outcome of seven-year follow-up. Pediatr Blood Cancer 2021;68:e29063. [PMID: 33871930 DOI: 10.1002/pbc.29063] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Sakr MA, Mohamed KAH, Hussein AM, Fouad MH, Allam AS, Safwat E. Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00090-y] [Reference Citation Analysis]
25 Qiu Z, Shen L, Jiang Y, Qiu J, Xu Z, Shi M, Yu Z, Ma Y, He W, Zheng Y, Li B, Wang G, Yuan Y. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study. Ann Transl Med 2021;9:283. [PMID: 33708910 DOI: 10.21037/atm-20-5360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
26 Monahan DS, Almas T, Wyile R, Cheema FH, Duffy GP, Hameed A. Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities. Drug Deliv Transl Res 2021;11:1924-42. [PMID: 33449342 DOI: 10.1007/s13346-020-00885-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Wang W, Wang L, Xie X, Yan Y, Li Y, Lu Q. A gene-based risk score model for predicting recurrence-free survival in patients with hepatocellular carcinoma. BMC Cancer 2021;21:6. [PMID: 33402113 DOI: 10.1186/s12885-020-07692-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Wang H, Yu H, Qian YW, Cao ZY, Wu MC, Cong WM. Postoperative adjuvant transcatheter arterial chemoembolization improves the prognosis of patients with huge hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021;20:232-9. [PMID: 33455865 DOI: 10.1016/j.hbpd.2020.12.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Wang X, Zhang H, Zhou L, Ou H, Liu H. Efficacy and Safety of 8 spheres Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Locally Advanced Non-small Cell Lung Cancer. Cancer Biother Radiopharm 2020. [PMID: 33332223 DOI: 10.1089/cbr.2020.4301] [Reference Citation Analysis]
30 Facciorusso A, Abd El Aziz MA, Tartaglia N, Ramai D, Mohan BP, Cotsoglou C, Pusceddu S, Giacomelli L, Ambrosi A, Sacco R. Microwave Ablation Versus Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials. Cancers (Basel) 2020;12:E3796. [PMID: 33339274 DOI: 10.3390/cancers12123796] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
31 Rossi SM, Murray T, McDonough L, Kelly H. Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities. Expert Opin Drug Deliv 2021;18:607-23. [PMID: 33253052 DOI: 10.1080/17425247.2021.1856074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chierici A, Ofosu A, Cincione I, Sacco R, Cotsoglou C, Facciorusso A. Transarterial chemoembolization as adjuvant treatment after surgery: The cure of huge hepatocellular carcinoma? Hepatobiliary Pancreat Dis Int 2021;20:205-6. [PMID: 33342662 DOI: 10.1016/j.hbpd.2020.12.005] [Reference Citation Analysis]
33 Torimura T, Iwamoto H. Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. Clin Mol Hepatol 2021;27:236-45. [PMID: 33317248 DOI: 10.3350/cmh.2020.0204] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
34 Vosshenrich J, Zech CJ, Heye T, Boldanova T, Fucile G, Wieland S, Heim MH, Boll DT. Response prediction of hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: unlocking the potential of CT texture analysis through nested decision tree models. Eur Radiol 2021;31:4367-76. [PMID: 33274405 DOI: 10.1007/s00330-020-07511-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
35 Chui AMN, Yau TCC, Cheung TT. An overview in management of hepatocellular carcinoma in Hong Kong using the Hong Kong Liver Cancer (HKLC) staging system. Glob Health Med 2020;2:312-8. [PMID: 33330826 DOI: 10.35772/ghm.2020.01062] [Reference Citation Analysis]
36 Cai L, Li H, Guo J, Zhao W, Duan Y, Hou X, Cheng L, Du H, Shao X, Diao Z, Li C. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study. Clin Res Hepatol Gastroenterol 2021;45:101535. [PMID: 33121882 DOI: 10.1016/j.clinre.2020.09.002] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
37 Bergamini C, Cavalieri S, Cascella T, Lanocita R, Alfieri S, Resteghini C, Platini F, Orlandi E, Locati LD, Marchianò A, Licitra L. Local therapies for liver metastases of rare head and neck cancers: a monoinstitutional case series. Tumori 2021;107:188-95. [PMID: 32924878 DOI: 10.1177/0300891620952844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Guo C, Wang C, Zhang J, Chen X. Treatment for Liver Tumor Using Combined Transarterial Embolization and Interaarterial Transfecting HIF-1α shRNA in a Rabbit VX2 Model. Onco Targets Ther 2020;13:8511-9. [PMID: 32904418 DOI: 10.2147/OTT.S262434] [Reference Citation Analysis]
39 Li Z, Xiao D, Li X, Zhan P, Wang J, Zhang H. Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA. Eur J Gastroenterol Hepatol 2019;31:885-92. [PMID: 30807446 DOI: 10.1097/MEG.0000000000001373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
40 Karina A, Benzina A, Tazhibayeva S, Fan H, Koole LH. Polymer microparticles with a cavity designed for transarterial chemo-embolization with crystalline drug formulations. J Biomed Mater Res B Appl Biomater 2021;109:401-9. [PMID: 32860336 DOI: 10.1002/jbm.b.34708] [Reference Citation Analysis]
41 Zhang Y, Zhang MW, Fan XX, Mao DF, Ding QH, Zhuang LH, Lv SY. Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma. World J Gastrointest Surg 2020; 12(8): 355-368 [PMID: 32903981 DOI: 10.4240/wjgs.v12.i8.355] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
42 Bian LF, Zhao XH, Gao BL, Zhang S, Ge GM, Zhan DD, Ye TT, Zheng Y. Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer. World J Gastroenterol 2020; 26(30): 4442-4452 [PMID: 32874056 DOI: 10.3748/wjg.v26.i30.4442] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Hulin A, Stocco J, Bouattour M. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clin Pharmacokinet 2019;58:983-1014. [PMID: 31093928 DOI: 10.1007/s40262-019-00740-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
44 Perfahl H, Jain HV, Joshi T, Horger M, Malek N, Bitzer M, Reuss M. Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC). Sci Rep 2020;10:10571. [PMID: 32601310 DOI: 10.1038/s41598-020-65012-1] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
45 Urbano J, Echevarria-uraga JJ, Ciampi-dopazo JJ, Sánchez-corral JA, Cobos Alonso J, Anton-ladislao A, Peña-baranda B, Nacarino-mejias V, González-costero R, Muñoz Ruiz-canela JJ, Pérez-cuesta J, Lanciego C, de Gregorio MA. Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma. European Journal of Radiology 2020;126:108966. [DOI: 10.1016/j.ejrad.2020.108966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
46 Facciorusso A, Bargellini I, Cela M, Cincione I, Sacco R. Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. Cancers (Basel) 2020;12:E897. [PMID: 32272656 DOI: 10.3390/cancers12040897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers (Basel) 2020;12:E791. [PMID: 32224882 DOI: 10.3390/cancers12040791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
48 Peisen F, Maurer M, Grosse U, Nikolaou K, Syha R, Ketelsen D, Artzner C, Bitzer M, Horger M, Grözinger G. Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE). Eur Radiol 2020;30:3782-92. [PMID: 32125515 DOI: 10.1007/s00330-020-06734-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
49 Baboci L, Capolla S, Di Cintio F, Colombo F, Mauro P, Dal Bo M, Argenziano M, Cavalli R, Toffoli G, Macor P. The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. J Oncol 2020;2020:4638192. [PMID: 32184825 DOI: 10.1155/2020/4638192] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
50 Gross A, Albrecht T. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. Cardiovasc Intervent Radiol 2020;43:402-10. [PMID: 31705244 DOI: 10.1007/s00270-019-02364-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
51 Habbel VSA, Zeile M, Stavrou GA, Wacker F, Brüning R, Oldhafer KJ, Rodt T. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:3463-79. [PMID: 31332502 DOI: 10.1007/s00261-019-02128-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
52 Malagari K, Moschouris H, Kiakidis T, Harward S, Kelekis A, Vrakas S, Koundouras D, Filipiadis D, Glantzounis G, Emmanouil E, Chatziioannou A, Vergadis V, Elefsiniotis I, Koskinas J, Dourakis S, Kelekis N. Five-Years Outcome Analysis of 142 Consecutive Hepatocellular Carcinoma Patients Treated with Doxorubicin Eluting Microspheres 30-60 μm: Results from a Single-Centre Prospective Phase II Trial. Cardiovasc Intervent Radiol 2019;42:1551-62. [PMID: 31321482 DOI: 10.1007/s00270-019-02260-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
53 Elshaarawy O, Gomaa A, Omar H, Rewisha E, Waked I. Intermediate stage hepatocellular carcinoma: a summary review. J Hepatocell Carcinoma. 2019;6:105-117. [PMID: 31372364 DOI: 10.2147/jhc.s168682] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
54 Karalli A, Teiler J, Haji M, Seth E, Brismar TB, Wahlin S, Axelsson R, Stål P. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. Scand J Gastroenterol 2019;54:905-12. [PMID: 31287338 DOI: 10.1080/00365521.2019.1632925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
55 Hagan A, Caine M, Press C, Macfarlane WM, Phillips G, Lloyd AW, Czuczman P, Kilpatrick H, Bascal Z, Tang Y, Garcia P, Lewis AL. Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods. Eur J Pharm Sci 2019;136:104943. [PMID: 31152772 DOI: 10.1016/j.ejps.2019.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
56 Xiang H, Long L, Yao Y, Fang Z, Zhang Z, Zhang Y. CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma. Technol Cancer Res Treat 2019;18:1533033819830751. [PMID: 30862264 DOI: 10.1177/1533033819830751] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
57 Lee SY, Choi JW, Lee JY, Kim DD, Kim HC, Cho HJ. Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor. Drug Deliv 2018;25:1472-83. [PMID: 29909706 DOI: 10.1080/10717544.2018.1480673] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
58 Li L, Zhao W, Wang M, Hu J, Wang E, Zhao Y, Liu L. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2018;18:138. [PMID: 30180810 DOI: 10.1186/s12876-018-0849-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
59 Sun G, Wang T, Li X, Li D, Peng Y, Wang X, Jia G, Su W, Cheng C, Yang J, Zuo C. Sub-Micrometer Au@PDA-125 I Particles as Theranostic Embolism Beads for Radiosensitization and SPECT/CT Monitoring. Adv Healthc Mater 2018;7:e1800375. [PMID: 29809314 DOI: 10.1002/adhm.201800375] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
60 Schoenberg SO, Attenberger UI, Solomon SB, Weissleder R. Developing a Roadmap for Interventional Oncology. Oncologist 2018;23:1162-70. [PMID: 29959284 DOI: 10.1634/theoncologist.2017-0654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]